Sahota, Amrik http://orcid.org/0000-0002-3603-673X
Tischfield, Jay A.
Goldfarb, David S.
Ward, Michael D.
Hu, Longqin
Funding for this research was provided by:
National Institute of Diabetes and Digestive and Kidney Diseases (R01DK112782)
Article History
Received: 19 September 2018
Accepted: 27 November 2018
First Online: 4 December 2018
Compliance ethical standards
:
: Dr. Goldfarb has received consulting fees from Retrophin. The other authors declare that they have no relevant financial interests. The work described in this manuscript on cystine diamides has been licensed by Rutgers University to PharmaKrysto. Rutgers University is the assignee of Patent Number US 9,248,453 B2 entitled “Cystine diamide analogs for the prevention of cystine stone formation in cystinuria” and New York University is the assignee of Patent Number US 8,450,089 B2 entitled “Compounds as L-cystine crystallization inhibitors and uses thereof”.
: All procedures performed in studies involving animals were in accordance with the ethical standards of the Institutional Animal Care and Use Committee of Rutgers University.